M&A Deal Summary |
|
|---|---|
| Date | 2014-09-04 |
| Target | Meda Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | DPT Laboratories |
| Sellers(s) | Meda |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1938 |
| Sector | Life Science |
DPT Laboratories Ltd. is a contract development and manufacturing organization (CDMO) with a specialized focus on semi-solid and liquid dosage forms.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2014 M&A | 1 of 1 |
Meda is an operator of an international specialty pharma company that is fully represented in Europe and the US through its own sales organizations in more than 50 countries. Meda’s products are sold in about 120 countries, and where it lacks a sales organization, it markets and sells its products via agents and other pharmaceutical companies. Meda has a diversified geographic footprint with approximately 62 percent of Meda's sales generated in Western Europe (the largest countries being Italy, Germany, France, and Sweden), 19 percent in Emerging Markets (driven by China, Russia, the Middle East, and Thailand) and 17 percent in the U.S. Meda has a network of seven manufacturing facilities in Europe, the U.S. and India. Meda is based in Solna, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2014 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-07-31 |
Rottapharm
Monza, Italy Rottapharm is an Italian drug company. It produces Dona, which is used to manage pain associated with osteoarthritis; Legalon, a treatment for liver disorders; and Reparil, an anti-inflammatory drug and pain reducer. |
Buy | $3.1B |
